Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Maternal serum screening for Down's syndrome, open neural tube defects andtrisomy 18
Autore:
Akbas, SH; Ozben, T; Alper, O; Ugur, A; Yucel, G; Luleci, G;
Indirizzi:
Akdeniz Univ, Fac Med, Dept Biochem, TR-07070 Antalya, Turkey Akdeniz Univ Antalya Turkey TR-07070 t Biochem, TR-07070 Antalya, Turkey Akdeniz Univ, Fac Med, Dept Med Genet, TR-07070 Antalya, Turkey Akdeniz Univ Antalya Turkey TR-07070 Med Genet, TR-07070 Antalya, Turkey
Titolo Testata:
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
fascicolo: 6, volume: 39, anno: 2001,
pagine: 487 - 490
SICI:
1434-6621(200106)39:6<487:MSSFDS>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN CHORIONIC-GONADOTROPIN; DIMERIC INHIBIN-A; ALPHA-FETOPROTEIN; FETAL ANEUPLOIDY; MARKERS; AGE;
Keywords:
Down's syndrome; trisomy 18; screening : maternal serum; alpha-fetoprotein; estradiol, unconjugated; human chorionic gonadotropin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
13
Recensione:
Indirizzi per estratti:
Indirizzo: Ozben, T Akdeniz Univ, Fac Med, Dept Biochem, TR-07070 Antalya, Turkey Akdeniz Univ Antalya Turkey TR-07070 , TR-07070 Antalya, Turkey
Citazione:
S.H. Akbas et al., "Maternal serum screening for Down's syndrome, open neural tube defects andtrisomy 18", CLIN CH L M, 39(6), 2001, pp. 487-490

Abstract

Maternal serum screening identifies women at an increased risk of a pregnancy with Down's syndrome or trisomy 18 or an open neural tube defect. The triple test, consisting of maternal serum alpha -fetoprotein, unconjugated estriol and human chorionic gonadotropin was carried out by a chemiluminescence immunoassay method in our laboratory. The study consisted of 373 pregnant women. The gestational range for the study group was 14-22 weeks. The mean maternal age for the study group was 28.53 +/- 5.46 years (range 17.4 to43.5 years); 9.1% of the women were considered at high risk for Down's syndrome based on the test results. In our study the detection rate for Down'ssyndrome by prenatal karyotyping was 66.6%. Maternal serum screening allows reduction of the number of women requiring amniocentesis without a significant decrease in the detection rate.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 07:06:37